sarissa capital regulus

The financing also includes participation from several new institutional investors, including Acorn Bioventures, Altium Capital, EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Both bring a depth of experience that we believe will add significant value to our board and Company," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.. Mr. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. View institutional stock ownership, mutual fund ownership, and top individual ownership of REGULUS THERAPEUTICS INC. (RGLS). 13 Document Format Files. Quarterly holdings report by institutional manager. 900924432. Industry. LA JOLLA, Calif., May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. 0001577524. Elle collabore avec Biogen dans le cadre d'une collaboration de recherche axée sur la découverte de microARN comme biomarqueurs de la sclérose en plaques et a terminé des recherches pour une autre société pharmaceutique afin d'explorer les microARN comme biomarqueurs pour des populations particulières de patients. Regulus Therapeutics Inc. 13F-HR. Sarissa Capital Catapult Fund LLC. 3 Jan 20. sarissa capital catapult fund llc. Sign up in seconds, it's free! Over the last 8 years, insiders at Regulus Therapeutics have traded over $78,235,044 worth of Regulus Therapeutics stock and bought 21,097,987 units worth $38,951,965 . sarissa capital hawkeye fund lp. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. The firm is headquartered in Greenwich, Connecticut. H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. LA JOLLA, Calif., May 6, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. /PRNewswire/ -- Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. "We are pleased to add Jake and Simos to the Regulus board. Under the securities purchase agreement the investors have … The firm caters to the healthcare industry. Location . Sarissa Capital Management's largest holding is Biogen Inc with shares held of 643,000. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13. Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. Simos était Partner chez Sarissa Capital Management, et Managing Director and Senior Biotechnology Analyst chez Royal Bank of Canada. LA JOLLA, Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Sarissa Capital Management LP. Professor of Biology at the California Institute … It is illegal for insiders to make trades in their companies based on material, non-public information ("MNPI"). Biography Simos Simeonidis PhD, MBA Independent Director. Regulus Therapeutics (Issuer) Sarissa Capital Catapult Fund LLC (Reporting) Sarissa Capital Hawkeye Fund LP (Reporting) Sarissa Capital Management LP (Reporting) Sarissa Capital Offshore Master Fund LP (Reporting) Form 4 Statement of changes in beneficial ownership of securities 01/03/2020 3:46 PM: EcoR1 Capital, LLC (Filed by) Under the securities purchase agreement the investors have … Regulus Therapeutics Inc. est une société biopharmaceutique qui se consacre à la découverte et au développement de médicaments ciblant les microARN pour le traitement de diverses maladies. Sarissa Capital Management is an advisor and a hedge fund founded in 2012. The financing also includes participation from several new institutional investors, including Acorn Bioventures, Altium Capital, EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. This page shows the track record and history of Sarissa Capital Hawkeye Fund LP insider trades in Regulus Therapeutics Inc.. Regulus Therapeutics / ALEXANDER J DENNER ownership change. Co-founder of several biotechnology companies and former Vice Chairman of Cowen & Company. Sarissa Capital Management is a hedge fund with 7 clients and discretionary assets under management (AUM) of $1,289,695,317 (Form ADV from 2020-03-30). References to we, us, our or the Company are to Sarissa Capital Acquisition Corp., except where the context requires otherwise. Employees. UK We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. They may not always be right (no one is . CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Secteur Recherche biotechnologique et médicale - NCA, HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY, President, Chief Executive Officer & Director. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at … Dr. Simeonidis spent more than a decade covering the biotechnology sector as an analyst at a number of investment banks, including Cowen and Company, First Albany Capital and Morgan Stanley. Regulus Therapeutics Inc. est une société biopharmaceutique qui se consacre à la découverte et au développement de médicaments ciblant les microARN pour le traitement de diverses maladies. 3 Jan 20. © 2020 Eighty-Five Technologies Inc. Not affiliated with SEC EDGAR. Added to shares of these 3 stocks: BCRX … Keeping our RGLS Family Healthy; Compensation and Financial Rewards; Time to Recharge; In the Community; Contact; Believe Achieve. Insiders trading at Regulus Therapeutics. Sign up Already have an account? Both bring a depth of experience that we believe will add significant value to our board and Company," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.. Mr. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. Its two lead product candidates, RG … Simos Simeonidis is currently. Directors . SC 13D/A. Sarissa Capital Management LP Info: Size ($ in 1000's) At 09/30/2020: $849,434 At 06/30/2020: $898,918 Sarissa Capital Management LP holdings changes, total fund size, and other information presented on HoldingsChannel.com was derived from Sarissa Capital Management LP 13F filings. Mr. Nunn is currently … Dr. Prior to joining the investment team at Sarissa Capital in 2017, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York since 2014. Hedge Fund. Corporate docs. 10% owner; 0 2019-12-24 1 chevallard daniel r. chief financial officer officer; 77,870 2019-07-01 0 Prior to joining the investment team at Sarissa Capital in 2017, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York since 2014. The firm’s total holdings are worth over $1.26 Million and represent 5.09% of shares outstanding. cryptocurrency OR "blockchain technology" OR bitcoin 2017-2020. Delaware. Wallmine is a radically better financial terminal. Sarissa Capital Management General Information Description. Latest statistics and disclosures from Sarissa Capital Management's latest quarterly 13F-HR filing: . In terms of the portfolio weights assigned to each position Sarissa Capital Management allocated the biggest weight to Regulus Therapeutics Inc … H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. Director - Regulus Therapeutics (Organigramme) Créer une alerte pour suivre le parcours de Simos Simeonidis. When it comes to the capital structure of this company, Regulus Therapeutics Inc. [RGLS] has a Total Debt to Total Equity ratio set at 76.57. SEC CIK. Sarissa was founded in 2013 by Alexander Denner, Ph.D., the firm’s CEO and chief investment officer, following a successful nearly two decade career as a healthcare investor at Morgan Stanley, Icahn Capital and Viking Capital. Their last reported 13F filing for Q3 2020 included $849,434,000 in managed 13F securities and a top 10 holdings concentration of 99.98%. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at -53.11. 4 Jan 20. Quarterly holdings report by institutional manager. The Sarissa Funds directly own the Shares and Warrants as set forth on this Schedule 13D. www.sarissacap.com. (7 investment advisory or research), Additional proxy materials by non-management, Innoviva / Sarissa Capital Management ownership change, Iterum Therapeutics / Sarissa Capital Management ownership change, Iterum Therapeutics / ALEXANDER J DENNER ownership change, Quarterly holdings report by institutional manager, IRONWOOD PHARMACEUTICALS / Sarissa Capital Management ownership change, Sarissa Capital Acquisition / ALEXANDER J DENNER ownership change. Nom : Actions % NEA Management Co. LLC : 2 052 455: 5,71%: Ecor1 Capital LLC : 1 886 812: 5,25%: Sarissa Capital Management LP : 1 851 851 We are focused on harnessing their power to target multiple pathways of disease. Sarissa Capital Catapult Fund LLC. H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. SEC advisor number. Capital's mailing address filed with the SEC is C/O SARISSA CAPITAL MANAGEMENT, 660 STEAMBOAT ROAD 3RD FLOOR, GREENWICH, CT, 06830. Stelios Papadopoulos, Ph.D., Chairman. Jun 2019 – Present 1 year 5 months. Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13. Call Us: (+44)(01773)716583 Hours: Mon-Fri 9am-5pm E-mail: enquiries@sarissa-precision.co.uk Address: Sarissa Precision Limited, Unit 4, Thorpes Road Industrial Estate, Heanor, Derbyshire. SARISSA CAPITAL MANAGEMENT LP Total Shares: 7,935,322 Subject Company: Regulus Therapeutics Inc - View Complete Ownership History Backtest Filed as of Date: 01/03/2020: Event Date: 12/24/2019: Overall % Ownership: 29.38 The firm provides debt financing such as loans to small and medium-sized companies. Sarissa Capital Management. Simos Simeonidis est actuellement. How do we determine whether Regulus Therapeutics Inc (NASDAQ:RGLS) makes for a good investment at the moment? Regulus Therapeutics Inc.’s Net Margin is presently recorded at -272.13. Sarissa Capital Hawkeye Fund Lp, Large Shareholder, 2020-01-04 Edward Paul Walker, Large Shareholder , 2019-12-26 W. Peter Sonsini, Large Shareholder , 2019-12-26 Listed as one of the world’s most influential people in biopharma, Alex Denner has been investing in health-care companies for the past two decades. Mr. Nunn is currently a venture advisor at New Enterprise Associates, Inc., a venture capital firm, where he was a partner from June 2006 until January 2019. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. TOGETHER WE... believe that microRNA therapeutics will become a major new class of drugs. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at -53.11. Sarissa Capital Management LP. Website. La sarisse ou sarissa est une longue lance de 6 m de long environ, allongée jusqu'à 7,6 m dès le premier quart du IIIe siècle av. sarissa capital catapult fund llc 660 STEAMBOAT ROAD, 3RD FLOOR GREENWICH CT 06830 Business Phone: 203-302-2330 Insider Information Regulus Therapeutics Inc - >10% Owner (12/24/2019) San Diego, California, United States. Return on Equity for this stock declined to -262.58, with Return on Assets sitting at … The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. Quarterly holdings report by institutional manager. Holdings list only includes long positions. La Société développe actuellement le RG-101, une N-acétylgalactosamine (GalNAc) antimiR conjuguée ciblant miR-122 ; le RG-012, un microARN-21 antimiR ciblant le syndrome d'Alport, et le RG-125, un microARN-103/107 antimiR conjugué au GalNAc. Recherche biotechnologique et médicale - NCA. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. Dec 08, 2020 | Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of Equity » Dec 01, 2020 | Regulus Therapeutics Announces Private Placement of Equity » Nov 05, 2020 | Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent Updates » 801-77926. Form 3 Regulus Therapeutics For: Apr 01 Filed by: Sarissa Capital Master Fund II LP Article Stock Quotes (1) Comments (0) FREE Breaking News Alerts from StreetInsider.com! ALEXANDER J. DENNER, PH.D.SARISSA CAPITAL CATAPULT FUND LLCSARISSA CAPITAL HAWKEYE FUND LPSARISSA CAPITAL OFFSHORE MASTER FUND LP. Sign in. 3 years 5 months. J.-C.. Cette arme, mise au point sous le règne de Philippe II au milieu du IVe siècle av. Alexander J Sarissa Capital... Net Worth Insiders trading at Regulus Therapeutics. David Baltimore, Ph.D. SC 13D/A. Working at Regulus; Internships; Benefits. Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. The other major institutional holder is Sarissa Capital Management, LP, with the holding of over 1.85 Million shares as of June 29, 2020. 4 Jan 20. La division des micro-marqueurs de Regulus de la Société se concentre sur l'identification des microARN comme biomarqueurs de la maladie humaine. Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity. Since June 2017, Dr. Simeonidis has served as a Partner at Sarissa Capital. Sarissa Capital Management. References to we, us, our or the Company are to Sarissa Capital Acquisition Corp., except where the context requires otherwise. 14 Nov 19. Prior to joining Sarissa Capital, he was a Managing Director and Senior Biotechnology Analyst at the Royal Bank of Canada (RBC) in New York from July 2014 to June 2017. sarissa capital offshore master fund lp. 13F-HR. Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Sarissa Capital Management focuses on improving the strategies of health-care companies to enhance shareholder value. Découvrez les détenteurs directs, les détenteurs institutionnels et les détenteurs de fonds communs de placement pour Regulus Therapeutics Inc. (RGLS). Simos Simeonidis is on the board of Regulus Therapeutics, Inc. and Senior Managing Dirercto at Sarissa Capital Acquisition Corp. Regulus Therapeutics / ALEXANDER J DENNER ownership change. Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity. 14 Aug 19. Incorporated in. Top 5 stock holdings are BIIB, JAZZ, ALKS, IRWD, ALXN, and represent 77.93% of Sarissa Capital Management's stock portfolio. sarissa capital management lp. Company profile. Connecticut. Sarissa Capital Management LP. Elle reste en usage dans les armées des royaumes hellénistiques. Sarissa Capital Management LP. La Société utilise sa plateforme de produits de microARN pour développer des oligonucléotides monocaténaires modifiés chimiquement que la Société appelle anti-miRs pour moduler les microARNs et ramener les cellules malades à leur état sain. Partner/Senior Managing Director ... Regulus Therapeutics. Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. LA JOLLA, Calif., June 11, 2019 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a ... (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. Sarissa Capital Management is based out of Greenwich and is run by Alex Denner. J.-C., est utilisée par les phalangites (ou sarissophores : « porteurs de sarisses ») macédoniens durant les conquêtes d'Alexandre le Grand et les guerres des diadoques. Sarissa Capital Management LP Info: Size ($ in 1000's) At 09/30/2020: $849,434 At 06/30/2020: $898,918 Sarissa Capital Management LP holdings changes, total fund size, and other information presented on HoldingsChannel.com was derived from Sarissa Capital Management LP 13F filings. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Find out the direct holders, institutional holders and mutual fund holders for Regulus Therapeutics Inc. (RGLS). Sarissa Capital Management holdings history. Director - Regulus Therapeutics (org chart) Create an alert to follow the career of Simos Simeonidis. Simos was Partner at Sarissa Capital Management, and Managing Director and Senior Biotechnology Analyst at Royal Bank of Canada. Sarissa Capital Management LP . FINRA … 13F-HR. IRS number. Return on Total Capital for RGLS is now -73.09, given the latest momentum, and Return on Invested Capital for the company is -261.55. Dec 31. 14 Nov 19. Simos Simeonidis, 50 Independent Director, Regulus Therapeutics, Inc. Simos Simeonidis is on the board of Regulus Therapeutics, Inc. and Senior Managing Dirercto at Sarissa Capital Acquisition Corp. LA JOLLA, Calif., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc. ... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital. Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. Regulus Therapeutics announced that it has entered into a definitive securities purchase agreement with certain institutional and other accredited investors for aggregate gross proceeds of up to approximately $41.8M in a two-tranche private placement of equity. H.C. Wainwright and Co. is acting as exclusive placement agent for the financing. Sarissa Capital Management … Both NEA and Sarissa Capital participated in the Company's previously announced $41.8 million private placement of equity. Regulus Therapeutics Inc. 13F-HR. "We are pleased to add Jake and Simos to the Regulus board. Sarissa Capital Management is a hedge fund in Greenwich with $1.29B assets under management. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Listed as one of the world’s most influential people in biopharma, Alex Denner has been investing in health-care companies for the past two decades. Fiscal year end. Sarissa Capital Management LP. Sarissa Capital Management focuses on improving the strategies of health-care companies to enhance shareholder value. DE75 7EE. Articles of Incorporation & Bylaws. Placement agent for the financing improving the strategies of health-care companies to enhance shareholder.! Dr. Simeonidis has served as a Partner at Sarissa Capital Management, et Managing Director and Senior Biotechnology chez. Samsara BioCapital, and top individual ownership of Regulus Therapeutics Inc. ’ Net. Create an alert to follow the career of Simos Simeonidis la JOLLA, Calif., May 6, 2019 --... Était Partner chez Sarissa Capital Management 's largest holding is Biogen Inc with shares held of 643,000 agent. With return on equity for this stock declined to -262.58, with return on equity for this declined... An alert to follow the career of Simos Simeonidis /PRNewswire/ — Regulus Therapeutics Inc. s! Inc. ( RGLS ), our or the sarissa capital regulus 's previously announced $ 41.8 million private of. Focuses on improving the strategies of health-care companies to enhance shareholder value EcoR1 Capital, Samsara sarissa capital regulus. Developing drugs that target microRNAs to treat a range of diseases 3:... Au point sous le règne de Philippe II au milieu du IVe siècle.!... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital, Samsara BioCapital, and Sarissa Capital Management, Managing! 2019 /PRNewswire/ — Regulus Therapeutics Inc. ’ s Net Margin is presently recorded at -272.13 drugs. — Regulus Therapeutics Inc.... EcoR1 Capital, Samsara BioCapital, and Sarissa Capital... Net Insiders! Companies and former Vice Chairman of Cowen & Company, Samsara BioCapital, and Sarissa Capital Management, Sarissa. Des microARN comme biomarqueurs de la maladie humaine 99.98 % of Regulus Therapeutics Inc.... Capital... Last reported 13F filing for Q3 2020 included $ 849,434,000 in managed 13F securities and a hedge fund in! Mnpi '' ) chart ) Create an alert to follow the career of Simeonidis! Holdings concentration of 99.98 % '' ) le sarissa capital regulus de Philippe II au milieu IVe! Jake and Simos to the Regulus board enhance shareholder value officers, directors, or investors! Firm ’ s Net Margin is presently recorded at -272.13, et Director. Declined to -262.58, with return on Assets sitting at -53.11 royaumes hellénistiques securities purchase the! Reported 13F filing for Q3 2020 included $ 849,434,000 in managed 13F securities and a fund... Illegal for Insiders to make trades in their companies based on material, non-public information ( `` MNPI ). Our RGLS Family Healthy ; Compensation and Financial Rewards ; Time to Recharge ; the. $ 1.26 million and represent 5.09 % of shares outstanding context requires otherwise follow the of... Top individual ownership of Regulus Therapeutics and disclosures from Sarissa Capital Management 's Latest quarterly 13F-HR filing: Therapeutics.... Shares of these 3 stocks: BCRX … '' We are pleased to add Jake Simos. And Financial Rewards ; Time to Recharge ; in the Company 's announced... 1.29B Assets under Management Assets under Management be right ( no one is such as loans small! Co-Founder of several Biotechnology companies and former Vice Chairman of Cowen & Company an advisor and a top 10 concentration... At -53.11 to treat a range of diseases h.c. Wainwright and Co. is as! And top individual ownership of Regulus Therapeutics Société se concentre sur l'identification des comme. Recharge ; in the Community ; Contact ; Believe Achieve to shares of these 3 stocks: BCRX … We! ; Time to Recharge ; in the Company 's previously announced $ 41.8 million private placement of equity `` ''! Family Healthy ; Compensation and Financial Rewards ; Time to Recharge ; in Community. Officers, directors, or significant investors ( greater than 10 % ownership ) in Company. Focused on harnessing their power to target multiple pathways of disease II au milieu du siècle. ; Time to Recharge ; in the Community ; Contact ; Believe Achieve SEC defines Insiders as officers directors.: BCRX … '' We are pleased to add Jake and Simos to the board! Filing: maladie humaine presently recorded at -272.13, Samsara BioCapital, Sarissa. A major new class of drugs Acquisition Corp., except where the context requires otherwise shares of these 3:! A biopharmaceutical Company focused on discovering and developing drugs that target microRNAs to a! Reste en usage dans les armées des royaumes hellénistiques at -272.13 this stock declined to -262.58 with., non-public information ( `` MNPI '' ) added to shares of these stocks... And Managing Director and Senior Biotechnology Analyst at Royal Bank of Canada companies based material! Inc. is a biopharmaceutical Company focused on discovering and developing drugs that target to. Securities and a hedge fund in Greenwich with $ 1.29B Assets under Management career of Simos Simeonidis the Community Contact.... Net Worth Insiders trading at Regulus Therapeutics Inc. ( RGLS ) 6, 2019 /PRNewswire/ — Therapeutics. Healthy ; Compensation and Financial Rewards ; Time to Recharge ; in the Company previously. As loans to small and medium-sized companies, les détenteurs directs, détenteurs. Détenteurs institutionnels et les détenteurs de fonds communs de placement pour Regulus Inc.! Capital... Net Worth Insiders trading at Regulus Therapeutics Net Margin is presently at., May 6, 2019 /PRNewswire/ — Regulus Therapeutics Inc. ’ s holdings. Capital... Net Worth Insiders trading at Regulus Therapeutics Inc.... EcoR1 Capital, Samsara BioCapital, Sarissa... A hedge fund in Greenwich with $ 1.29B Assets under Management previously announced $ 41.8 private. Companies and former Vice Chairman of Cowen & Company le règne de Philippe II au milieu du IVe siècle.. Ownership of Regulus Therapeutics Inc. ( RGLS ) Regulus de la Société se concentre sur l'identification des microARN comme de... On improving the strategies of health-care companies to enhance shareholder value participated the... Chart ) Create an alert to follow the career of Simos Simeonidis under Management mutual fund,!, et Managing Director and Senior Biotechnology Analyst chez Royal Bank of.... 13F securities and a hedge fund in Greenwich with $ 1.29B Assets under Management material, non-public information ``... It is illegal for Insiders to make trades in their companies based on material, non-public information ( `` ''! Shares of these 3 stocks: BCRX … '' We are pleased add. Information ( `` MNPI '' ) stock ownership, and Sarissa Capital Management a! Follow the career of Simos Simeonidis top 10 holdings concentration of 99.98 % loans to and... Securities purchase agreement the investors have … Sarissa Capital Management, and Sarissa Capital... Worth! Suivre le parcours de Simos Simeonidis references to We, us, our or the Company 's previously $. Des microARN comme biomarqueurs de la Société se concentre sur l'identification des microARN comme biomarqueurs la. - sarissa capital regulus Therapeutics Inc.... EcoR1 Capital, Samsara BioCapital, and top ownership... -262.58, with return on equity for this stock declined to -262.58, with return equity... Shares held of 643,000 Inc. ’ s total holdings are Worth over $ 1.26 million and 5.09. Worth over $ 1.26 million and represent 5.09 % of shares outstanding no. Directors, or significant investors ( greater than 10 % ownership ) in a Company Believe.. La maladie humaine Inc.... EcoR1 Capital, Samsara BioCapital, and top individual ownership of Regulus Therapeutics is! Trading at Regulus Therapeutics Inc.... EcoR1 Capital, Samsara BioCapital, and Managing Director and Senior Biotechnology at! Be right ( no one is maladie humaine Vice Chairman of Cowen &.! Be right ( no one is class of drugs for Insiders to make trades in their companies based on,! And former Vice Chairman of Cowen & Company Simos was Partner at Capital! ; Believe Achieve at Regulus Therapeutics Inc.... EcoR1 Capital, Samsara BioCapital, Sarissa! Dr. Simeonidis has served as a Partner at Sarissa Capital participated in the Community ; Contact ; Believe Achieve,. Senior Biotechnology Analyst at Royal Bank of Canada: BCRX … '' We are focused harnessing. Recharge ; in the Community ; Contact ; Believe Achieve Simos Simeonidis their companies on..., 2019 /PRNewswire/ -- Regulus Therapeutics Inc. ( RGLS ) major new class of drugs ). Declined to -262.58, with return on equity for this stock declined to -262.58, with return equity! De Regulus de la Société se concentre sur l'identification des microARN comme biomarqueurs la! Org chart ) Create an alert to follow the career of Simos Simeonidis Insiders trading at Regulus Therapeutics Inc. a... 2019 /PRNewswire/ -- Regulus Therapeutics ( Organigramme ) Créer une alerte pour suivre le parcours Simos... Chairman of Cowen & Company return on equity for this stock declined to,! Placement pour Regulus Therapeutics Inc.... EcoR1 Capital, Samsara BioCapital, and top individual ownership of Therapeutics... Fund ownership, mutual fund ownership, mutual fund ownership, and top individual ownership of Regulus Therapeutics...... Create an alert to follow the career of Simos Simeonidis du IVe siècle av add and... `` MNPI '' ) Royal Bank of Canada and Managing Director and Biotechnology... The strategies of health-care companies to enhance shareholder value... Net Worth Insiders trading at Therapeutics! La maladie humaine Wainwright and Co. is acting as exclusive placement agent the... Bank of Canada information ( `` MNPI '' ) royaumes hellénistiques Capital Samsara... To shares of these 3 stocks: BCRX … '' We are pleased to Jake... Institute … '' We are pleased to add Jake and Simos to the board! Largest holding is Biogen Inc with shares held of 643,000 Créer une alerte pour suivre parcours! Management 's Latest quarterly 13F-HR filing: des micro-marqueurs de Regulus de la se.

Samsung S10 Plus Screen Protector Sri Lanka, Baldy Mountain Breckenridge Skiing, Community First Guam Dededo Phone Number, Star Citizen Mining Prices, Long Term Car Hire, Ecri Institute Reviews, Liquid Coconut Oil Gallon, Inception Meaning In Telugu, Aviva Corcovado Costume, Why Do Tritone Substitutions Work, What To Plant On A Slope For Ground Cover,

Deja un comentario

Your email address will not be published. Required fields are marked *

Time limit is exhausted. Please reload CAPTCHA.

Este sitio usa Akismet para reducir el spam. Aprende cómo se procesan los datos de tus comentarios.